Barclays Portfolio holdings
Barclays is a British universal bank whose roots go back to 1690, when the Quakers John Freame and Thomas Gould started a goldsmith banking business in London. The Barclays name came into the business in 1736, when James Barclay, son-in-law of founder John Freame, became a partner. Barclays launched the UK's first credit card, Barclaycard, in 1966, and in 1967 put the world's first cash machine in a branch in Enfield. In 2008 Barclays bought the North American operations of Lehman Brothers, and in 2009 it sold its Barclays Global Investors unit, home of the iShares ETFs, to BlackRock. It runs five divisions: UK consumer banking, UK corporate banking, private banking and wealth management, an investment bank and a US consumer bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$17.5B |
| 2 |
NVIDIA
NVDA
|
+$2.7B |
| 3 |
Intel
INTC
|
+$1.98B |
| 4 |
Broadcom
AVGO
|
+$1.46B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.11B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$35.8B |
| 2 |
Apple
AAPL
|
+$1.83B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$913M |
| 4 |
Microsoft
MSFT
|
+$856M |
| 5 |
Bank of America
BAC
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.47% |
| 2 | Technology | 19.84% |
| 3 | Consumer Discretionary | 7.61% |
| 4 | Financials | 5.61% |
| 5 | Communication Services | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2551
Pitney Bowes
PBI
$2.15B
| $2.06M | ﹤0.01% |
126,519
+39,570
| +46% | +$683K |
2013 Q2
53 quarters
|
|
2552
KT
KT
$8.95B
| $2.06M | ﹤0.01% |
108,897
+2,651
| +2% | +$49.9K |
2026 Q1
2 quarters
|
|
2553
PUT
Accenture
ACN
$151B
| $2.05M | ﹤0.01% |
+11,200
| New | +$1.89M |
2026 Q3
0 quarters
|
|
2554
Integra LifeSciences
IART
$1.14B
| $2.05M | ﹤0.01% |
126,114
+108,467
| +615% | +$1.87M |
2016 Q1
42 quarters
|
|
2555
Danaos Corp
DAC
$2.73B
| $2.05M | ﹤0.01% |
13,291
+1,083
| +9% | +$156K |
2026 Q2
1 quarter
|
|
2556
Xeris Biopharma Holdings
XERS
$3.03B
| $2.05M | ﹤0.01% |
213,980
+47,414
| +28% | +$400K |
2022 Q1
18 quarters
|
|
2557
Sable Offshore Corp
SOC
$126M
| $2.05M | ﹤0.01% |
591,189
-334,900
| -36% | -$1.49M |
2024 Q2
9 quarters
|
|
2558
Stepan Co
SCL
$1.5B
| $2.04M | ﹤0.01% |
32,782
+5,077
| +18% | +$313K |
2013 Q2
53 quarters
|
|
2559
Central Garden & Pet Co Class A
CENTA
$2.56B
| $2.04M | ﹤0.01% |
60,995
-138,525
| -69% | -$5.14M |
2016 Q1
42 quarters
|
|
2560
AtriCure
ATRC
$2.93B
| $2.03M | ﹤0.01% |
36,172
+8,590
| +31% | +$387K |
2013 Q2
53 quarters
|
|
2561
PUT
CVS Health
CVS
$115B
| $2.03M | ﹤0.01% |
23,700
-118,600
| -83% | -$11.6M |
2024 Q3
8 quarters
|
|
2562
Ooma
OOMA
$507M
| $2.02M | ﹤0.01% |
98,795
-3,735
| -4% | -$79.8K |
2017 Q1
38 quarters
|
|
2563
QuinStreet
QNST
$1.14B
| $2.02M | ﹤0.01% |
134,306
+36,306
| +37% | +$638K |
2016 Q3
40 quarters
|
|
2564
Alliance Resource Partners
ARLP
$3.26B
| $2.01M | ﹤0.01% |
82,751
+48,924
| +145% | +$1.24M |
2025 Q2
5 quarters
|
|
2565
Taysha Gene Therapies
TSHA
$1.35B
| $2.01M | ﹤0.01% |
412,721
-1,217,938
| -75% | -$7.02M |
2024 Q2
9 quarters
|
|
2566
Trustmark
TRMK
$2.72B
| $2.01M | ﹤0.01% |
44,795
+11,879
| +36% | +$555K |
2013 Q2
53 quarters
|
|
2567
Kontoor Brands
KTB
$4.37B
| $2.01M | ﹤0.01% |
31,830
+14,572
| +84% | +$1.13M |
2019 Q2
29 quarters
|
|
2568
Ocular Therapeutix
OCUL
$1.42B
| $2.01M | ﹤0.01% |
261,436
+10,746
| +4% | +$105K |
2014 Q4
47 quarters
|
|
2569
Credit Acceptance
CACC
$5.18B
| $2.01M | ﹤0.01% |
3,776
-13,049
| -78% | -$7.74M |
2016 Q2
41 quarters
|
|
2570
Casella Waste Systems
CWST
$6.26B
| $2M | ﹤0.01% |
24,907
+13,334
| +115% | +$1.22M |
2013 Q2
53 quarters
|
|
2571
Sagimet Biosciences
SGMT
$778M
| $2M | ﹤0.01% |
202,396
-25,535
| -11% | -$235K |
2025 Q3
4 quarters
|
|
2572
Global Net Lease
GNL
$1.49B
| $2M | ﹤0.01% |
242,043
-293,973
| -55% | -$2.63M |
2016 Q3
40 quarters
|
|
2573
Anterix
ATEX
$1.61B
| $1.99M | ﹤0.01% |
25,405
+23,064
| +985% | +$2.12M |
2022 Q1
18 quarters
|
|
2574
Biohaven
BHVN
$2.22B
| $1.99M | ﹤0.01% |
149,287
+16,328
| +12% | +$236K |
2022 Q4
15 quarters
|
|
2575
Ethan Allen Interiors
ETD
$451M
| $1.99M | ﹤0.01% |
95,272
+10,199
| +12% | +$230K |
2013 Q2
53 quarters
|
|
Similar funds
Barclays's Q3 2026 Portfolio in Review
As of Q3 2026, Barclays held 5,855 positions worth $500B, down 4% from $521B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays withdrew a net $19B in Q3 2026, closing 474 positions and reducing 1,494 holdings. Its most notable exit was ExxonMobil, an estimated $761M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, down from 55% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares Broad USD High Yield Corporate Bond ETF worth $199M.
- Barclays's largest Q3 2026 buy was iShares Broad USD High Yield Corporate Bond ETF: 5,582,517 shares worth $199M.
- Barclays added most to Tesla in Q3 2026, an estimated $17.5B increase.
- Barclays's biggest Q3 2026 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $35.8B.
- Barclays fully exited ExxonMobil in Q3 2026, selling an estimated $761M.
- Barclays's ten largest holdings make up 40% of its $500B portfolio in Q3 2026.
- Barclays opened 525 new positions and closed 474 in Q3 2026.
- Barclays's portfolio value fell 4% quarter-over-quarter to $500B.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.